Logo image of AZTA

AZENTA INC (AZTA) Stock Fundamental Analysis

NASDAQ:AZTA - Nasdaq - US1143401024 - Common Stock - Currency: USD

29.03  -0.1 (-0.34%)

After market: 29.03 0 (0%)

Fundamental Rating

4

Overall AZTA gets a fundamental rating of 4 out of 10. We evaluated AZTA against 54 industry peers in the Life Sciences Tools & Services industry. While AZTA has a great health rating, there are worries on its profitability. AZTA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AZTA was profitable.
In the past year AZTA had a positive cash flow from operations.
In multiple years AZTA reported negative net income over the last 5 years.
Of the past 5 years AZTA 4 years had a positive operating cash flow.
AZTA Yearly Net Income VS EBIT VS OCF VS FCFAZTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

1.2 Ratios

AZTA's Return On Assets of -3.20% is in line compared to the rest of the industry. AZTA outperforms 55.56% of its industry peers.
AZTA has a Return On Equity of -3.84%. This is comparable to the rest of the industry: AZTA outperforms 57.41% of its industry peers.
Industry RankSector Rank
ROA -3.2%
ROE -3.84%
ROIC N/A
ROA(3y)16.36%
ROA(5y)11.87%
ROE(3y)17.86%
ROE(5y)13.45%
ROIC(3y)N/A
ROIC(5y)N/A
AZTA Yearly ROA, ROE, ROICAZTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

1.3 Margins

AZTA has a Gross Margin (43.08%) which is in line with its industry peers.
AZTA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for AZTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.44%
GM growth 5Y-0.19%
AZTA Yearly Profit, Operating, Gross MarginsAZTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

More info and screens

8

2. Health

2.1 Basic Checks

AZTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AZTA has less shares outstanding
The number of shares outstanding for AZTA has been reduced compared to 5 years ago.
The debt/assets ratio for AZTA is higher compared to a year ago.
AZTA Yearly Shares OutstandingAZTA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
AZTA Yearly Total Debt VS Total AssetsAZTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 3.85 indicates that AZTA is not in any danger for bankruptcy at the moment.
AZTA's Altman-Z score of 3.85 is fine compared to the rest of the industry. AZTA outperforms 75.93% of its industry peers.
There is no outstanding debt for AZTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.85
ROIC/WACCN/A
WACC10.28%
AZTA Yearly LT Debt VS Equity VS FCFAZTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

AZTA has a Current Ratio of 3.22. This indicates that AZTA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.22, AZTA perfoms like the industry average, outperforming 53.70% of the companies in the same industry.
A Quick Ratio of 2.84 indicates that AZTA has no problem at all paying its short term obligations.
The Quick ratio of AZTA (2.84) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.22
Quick Ratio 2.84
AZTA Yearly Current Assets VS Current LiabilitesAZTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

4

3. Growth

3.1 Past

AZTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.89%, which is quite impressive.
Measured over the past years, AZTA shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -12.07% on average per year.
Looking at the last year, AZTA shows a decrease in Revenue. The Revenue has decreased by -1.32% in the last year.
The Revenue has been decreasing by -3.41% on average over the past years.
EPS 1Y (TTM)38.89%
EPS 3Y-45.83%
EPS 5Y-12.07%
EPS Q2Q%18.75%
Revenue 1Y (TTM)-1.32%
Revenue growth 3Y8.51%
Revenue growth 5Y-3.41%
Sales Q2Q%-16.71%

3.2 Future

The Earnings Per Share is expected to grow by 29.43% on average over the next years. This is a very strong growth
AZTA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.23% yearly.
EPS Next Y9.63%
EPS Next 2Y38.73%
EPS Next 3Y37.52%
EPS Next 5Y29.43%
Revenue Next Year-8.99%
Revenue Next 2Y-2.37%
Revenue Next 3Y0.02%
Revenue Next 5Y2.23%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AZTA Yearly Revenue VS EstimatesAZTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
AZTA Yearly EPS VS EstimatesAZTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2 2.5

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

AZTA is valuated quite expensively with a Price/Earnings ratio of 58.06.
Compared to the rest of the industry, the Price/Earnings ratio of AZTA is on the same level as its industry peers.
AZTA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.48.
AZTA is valuated quite expensively with a Price/Forward Earnings ratio of 36.79.
AZTA's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.04, AZTA is valued at the same level.
Industry RankSector Rank
PE 58.06
Fwd PE 36.79
AZTA Price Earnings VS Forward Price EarningsAZTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

61.11% of the companies in the same industry are more expensive than AZTA, based on the Enterprise Value to EBITDA ratio.
The rest of the industry has a similar Price/Free Cash Flow ratio as AZTA.
Industry RankSector Rank
P/FCF 51.31
EV/EBITDA 29.65
AZTA Per share dataAZTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AZTA does not grow enough to justify the current Price/Earnings ratio.
AZTA's earnings are expected to grow with 37.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)6.03
PEG (5Y)N/A
EPS Next 2Y38.73%
EPS Next 3Y37.52%

More info and screens

0

5. Dividend

5.1 Amount

AZTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AZENTA INC

NASDAQ:AZTA (8/8/2025, 8:20:14 PM)

After market: 29.03 0 (0%)

29.03

-0.1 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-10 2025-11-10/amc
Inst Owners117.02%
Inst Owner ChangeN/A
Ins Owners0.65%
Ins Owner Change3.49%
Market Cap1.33B
Analysts52.31
Price Target32.64 (12.44%)
Short Float %10.74%
Short Ratio5.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.64%
Min EPS beat(2)-29.97%
Max EPS beat(2)37.26%
EPS beat(4)3
Avg EPS beat(4)50.46%
Min EPS beat(4)-29.97%
Max EPS beat(4)122.72%
EPS beat(8)7
Avg EPS beat(8)229.99%
EPS beat(12)10
Avg EPS beat(12)156.19%
EPS beat(16)13
Avg EPS beat(16)121%
Revenue beat(2)0
Avg Revenue beat(2)-0.65%
Min Revenue beat(2)-1.07%
Max Revenue beat(2)-0.22%
Revenue beat(4)1
Avg Revenue beat(4)-0.27%
Min Revenue beat(4)-1.7%
Max Revenue beat(4)1.9%
Revenue beat(8)4
Avg Revenue beat(8)0.73%
Revenue beat(12)5
Avg Revenue beat(12)-0.93%
Revenue beat(16)7
Avg Revenue beat(16)-8.04%
PT rev (1m)-18.09%
PT rev (3m)-36.35%
EPS NQ rev (1m)3.34%
EPS NQ rev (3m)-3.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.37%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)0.05%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.53%
Valuation
Industry RankSector Rank
PE 58.06
Fwd PE 36.79
P/S 2.1
P/FCF 51.31
P/OCF 22.26
P/B 0.78
P/tB 1.46
EV/EBITDA 29.65
EPS(TTM)0.5
EY1.72%
EPS(NY)0.79
Fwd EY2.72%
FCF(TTM)0.57
FCFY1.95%
OCF(TTM)1.3
OCFY4.49%
SpS13.84
BVpS37.17
TBVpS19.82
PEG (NY)6.03
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.2%
ROE -3.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.08%
FCFM 4.09%
ROA(3y)16.36%
ROA(5y)11.87%
ROE(3y)17.86%
ROE(5y)13.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.44%
GM growth 5Y-0.19%
F-Score7
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 43.02%
Cap/Sales 5.33%
Interest Coverage N/A
Cash Conversion 190.21%
Profit Quality N/A
Current Ratio 3.22
Quick Ratio 2.84
Altman-Z 3.85
F-Score7
WACC10.28%
ROIC/WACCN/A
Cap/Depr(3y)77.14%
Cap/Depr(5y)74.64%
Cap/Sales(3y)8.52%
Cap/Sales(5y)9.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.89%
EPS 3Y-45.83%
EPS 5Y-12.07%
EPS Q2Q%18.75%
EPS Next Y9.63%
EPS Next 2Y38.73%
EPS Next 3Y37.52%
EPS Next 5Y29.43%
Revenue 1Y (TTM)-1.32%
Revenue growth 3Y8.51%
Revenue growth 5Y-3.41%
Sales Q2Q%-16.71%
Revenue Next Year-8.99%
Revenue Next 2Y-2.37%
Revenue Next 3Y0.02%
Revenue Next 5Y2.23%
EBIT growth 1Y41.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1002.73%
EBIT Next 3Y152.61%
EBIT Next 5YN/A
FCF growth 1Y105.18%
FCF growth 3Y-48.98%
FCF growth 5Y-28.07%
OCF growth 1Y113.28%
OCF growth 3Y-30.52%
OCF growth 5Y-11.17%